Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 144,80k | Derivative Exercise and Sale | 3,62 | 300,44k | - |
| 2026-06-05 | Dr. Najat KhanCEO, President & Director | -23,59k | 84,46k | Automatic Disposition | 3,58 | 108,54k | -17,85% |
| 2026-06-02 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 110,40k | Automatic Disposition | 3,68 | 6,15M | -0,49% |
| 2026-06-03 | Dr. Namandje N. BumpusIndependent Director | -4,39k | 15,53k | Automatic Disposition | 3,54 | 43,17k | -9,22% |
| 2026-05-22 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 123,20k | Derivative Exercise and Sale | 3,08 | 300,44k | - |
| 2026-05-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -25,02k | 76,05k | Sale to Issuer | 3,04 | 285,58k | -8,05% |
| 2026-05-15 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -22,82k | 69,38k | Sale to Issuer | 3,04 | 300,44k | -7,06% |
| 2026-05-15 | Dr. David HallettChief Scientific Officer | -26,66k | 81,04k | Sale to Issuer | 3,04 | 406,65k | -6,15% |
| 2026-05-15 | Dr. Najat KhanCEO, President & Director | -62,70k | 190,61k | Sale to Issuer | 3,04 | 132,13k | -32,18% |
| 2026-05-07 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 134,80k | Derivative Exercise and Sale | 3,37 | 244,17k | - |
| 2026-05-05 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 105,60k | Automatic Disposition | 3,52 | 6,18M | -0,48% |
| 2026-04-22 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 144,40k | Derivative Exercise and Sale | 3,61 | 244,17k | - |
| 2026-04-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -48,03k | 149,37k | Sale to Issuer | 3,11 | 257,37k | -15,73% |
| 2026-04-07 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 93,00k | Automatic Disposition | 3,10 | 6,21M | -0,48% |
| 2026-04-07 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 124,00k | Derivative Exercise and Sale | 3,10 | 244,17k | - |
| 2026-03-23 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 130,00k | Derivative Exercise and Sale | 3,25 | 244,17k | - |
| 2026-03-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,96k | 26,97k | Automatic Disposition | 3,39 | 203,21k | -3,77% |
| 2026-03-16 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,08k | 24,20k | Sale to Issuer | 3,42 | 203,21k | -3,36% |
| 2026-03-09 | Dr. Najat KhanCEO, President & Director | -28,30k | 94,66k | Automatic Disposition | 3,35 | 40,73k | -40,99% |
| 2026-03-09 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -20,00k | 0,00 | Derivative Exercise and Sale | - | 244,17k | - |
| 2026-03-03 | Dr. Blake C. BorgesonIndependent Director | -170,00k | 588,20k | Verkauf | 3,46 | 6,24M | -2,65% |
| 2026-02-17 | Dr. David HallettChief Scientific Officer | -11,91k | 41,56k | Sale to Issuer | 3,49 | 382,79k | -3,02% |
| 2026-02-18 | Mr. Ben R. TaylorCFO & President of Recursion UK | -13,43k | 41,35k | Automatic Disposition | 3,08 | 203,23k | -6,20% |
| 2026-02-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 41,56k | Sale to Issuer | 3,49 | 203,23k | -5,54% |
| 2026-02-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 138,40k | Derivative Exercise and Sale | 3,46 | 244,17k | - |
| 2026-02-17 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -27,27k | 95,15k | Sale to Issuer | 3,49 | 244,17k | -10,04% |
| 2026-02-17 | Dr. Najat KhanCEO, President & Director | -14,28k | 49,84k | Sale to Issuer | 3,49 | 69,03k | -17,14% |
| 2026-02-06 | Dr. David HallettChief Scientific Officer | -11,40k | 45,37k | Sale to Issuer | 3,98 | 300,78k | -3,65% |
| 2026-02-06 | Dr. Najat KhanCEO, President & Director | -10,36k | 41,25k | Sale to Issuer | 3,98 | 33,81k | -23,46% |
| 2026-02-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,40k | 45,37k | Sale to Issuer | 3,98 | 203,23k | -5,31% |
| 2026-02-03 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 924,00k | Automatic Disposition | 4,20 | 6,41M | -3,32% |
| 2026-02-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 164,80k | Derivative Exercise and Sale | 4,12 | 179,33k | - |
| 2026-02-06 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -10,36k | 36,90k | Sale to Issuer | 3,56 | 179,33k | -5,46% |
| 2026-01-20 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 178,80k | Derivative Exercise and Sale | 4,47 | 159,35k | - |
| 2026-01-06 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 959,20k | Automatic Disposition | 4,36 | 6,63M | -3,21% |
| 2026-01-05 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 170,00k | Derivative Exercise and Sale | 4,25 | 159,35k | - |
| 2025-12-29 | Mr. Ben R. TaylorCFO & President of Recursion UK | -21,38k | 89,38k | Automatic Disposition | 4,18 | 190,38k | -10,10% |
| 2025-12-22 | Dr. Najat KhanCEO, President & Director | -124,40k | 548,59k | Automatic Disposition | 4,41 | 13,83k | -90,00% |
| 2025-12-18 | Mubadala Investment Company PJSCUnternehmen | -12,99M | 56,59M | Verkauf | 4,24 - 4,58 | 0,00 | -100,00% |
| 2025-12-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 180,00k | Derivative Exercise and Sale | 4,50 | 159,35k | - |
| 2025-12-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 30,56k | Sale to Issuer | 4,33 | 211,76k | -3,23% |
| 2025-12-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 185,20k | Derivative Exercise and Sale | 4,63 | 159,35k | - |
| 2025-12-02 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 961,40k | Automatic Disposition | 4,37 | 6,85M | -3,11% |
| 2025-11-25 | Mr. Ben R. TaylorCFO & President of Recursion UK | -2,27k | 9,15k | Sale to Issuer | 4,03 | 203,81k | -1,10% |
| 2025-11-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 49,30k | Sale to Issuer | 4,14 | 201,25k | -5,59% |
| 2025-11-17 | Dr. Najat KhanCEO, President & Director | -17,58k | 72,80k | Sale to Issuer | 4,14 | 138,23k | -11,29% |
| 2025-11-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 166,40k | Derivative Exercise and Sale | 4,16 | 159,35k | - |
| 2025-11-17 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,39k | 167,21k | Sale to Issuer | 4,14 | 159,35k | -20,22% |
| 2025-11-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 208,40k | Derivative Exercise and Sale | 5,21 | 107,63k | - |
| 2025-10-23 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 570,00k | Derivative Exercise and Sale | 5,70 | 107,63k | - |
| 2025-10-10 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -120,00k | 604,00k | Derivative Exercise and Sale | 6,04 | 100,66k | - |
| 2025-09-25 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 476,00k | Derivative Exercise and Sale | 4,76 | 107,63k | - |
| 2025-09-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 34,09k | Sale to Issuer | 4,83 | 187,82k | -3,62% |
| 2025-09-10 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -120,00k | 471,00k | Derivative Exercise and Sale | 4,71 | 107,63k | - |
| 2025-08-26 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 484,00k | Derivative Exercise and Sale | 4,84 | 107,63k | - |
| 2025-08-18 | Dr. Najat KhanCEO, President & Director | -36,60k | 202,17k | Verkauf | 5,52 | 111,62k | -24,69% |
| 2025-08-15 | Dr. Najat KhanCEO, President & Director | -3,79k | 21,37k | Sale to Issuer | 5,64 | 111,62k | -3,28% |
| 2025-08-15 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,39k | 227,80k | Sale to Issuer | 5,64 | 107,63k | -27,29% |
| 2025-08-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 67,16k | Sale to Issuer | 5,64 | 179,86k | -6,21% |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -541,54k | 2,86M | Derivative Exercise and Sale | 5,28 | 55,91k | - |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -76,63k | 404,63k | Automatic Disposition | 5,28 | 55,91k | -57,82% |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -10,00k | 0,00 | Other Disposition | - | 55,91k | -15,17% |
| 2025-06-16 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 34,72k | Sale to Issuer | 4,92 | 166,44k | -4,07% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
